111 (NASDAQ:YI) versus Elevance Health (NYSE:ELV) Financial Analysis

Elevance Health (NYSE:ELV) and 111 (NASDAQ:YI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Elevance Health and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0	8	15	0	2.65
111	1	0	0	0	1.00

Elevance Health presently has a consensus target price of $440.90, indicating a potential upside of 13.12%. Given Elevance Health’s stronger consensus rating and higher possible upside, analysts plainly believe Elevance Health is more favorable than 111.

Institutional and Insider Ownership

89.2% of Elevance Health shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 0.3% of Elevance Health shares are held by insiders. Comparatively, 43.9% of 111 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Elevance Health has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, 111 has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares Elevance Health and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.47%	14.64%	5.22%
111	-1.01%	N/A	-4.86%

Earnings and Valuation

This table compares Elevance Health and 111″s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$201.11 billion	0.42	$5.66 billion	$22.50	17.32
111	$10.48 billion	0.00	-$9.65 million	($1.60)	-2.24

Elevance Health has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than Elevance Health, indicating that it is currently the more affordable of the two stocks.

Summary

Elevance Health beats 111 on 13 of the 14 factors compared between the two stocks.

About Elevance Health

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.